Description
Reversibly inhibits dihyroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines, preventing DNA synthesis of activated lymphocytes (IC50s = 0.09, 3.5, and 12.5 μM for rat, mouse, and human, respectively); also inhibits tyrosine kinases responsible for early T cell and B cell cycling and the production of PGE2, MMP-1, and IL-6 in immune-activated synoviocytes
Formal name: 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2Z-butenamide
Synonyms: Flucyamide|HMR 1726|SU 20|Teriflunomide
Molecular weight: 270.2
CAS: 163451-81-8
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Cycle||Research Area|Cell Biology|Proteolysis|Cytosolic & Secreted Proteases||Research Area|Epigenetics, Transcription, & Translation|RNA, DNA, & Protein Synthesis||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Immunology & Inflammation|Innate Immunity